Akeso Inc
-
Ivonescimab: lung cancer treatment breakthroughs from AKESO
Ivonescimab (PD-1/VEGF BsAbs,AK112), developed independently by Akeso, Inc, is the world’s first PD-1/VEGF bispecific antibody for clinical trail. Ivonescimab injection(AK112) has received 3 breakthrough therapy designation(BTD) for NSCLC.
